Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Learn when bonds may outperform stocks for retirement, with practical timing cues and risk considerations.
24,889 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
As oil prices surge toward triple digits, Trump volleyed calls for immediate rate cuts from Powell. The Fed appears p...
Kraft Heinz reports solid free cash flow while store-brand competition erodes volumes, prompting a pivot away from a ...
A notable fund pulled out of a multi-million dollar DNOW position last quarter, triggering questions about strategy a...
Paysign stock skyrocketing today has traders buzzing about a rapid move in a healthcare fintech company. This guide b...
Red Cat Holdings posted a record Q4 revenue of $26.2 million and full-year $40.7 million, but margins stayed thin and...
As Zymeworks gears up for 2026 earnings, investors should focus on cash runway, pipeline milestones, and collaboratio...
Wells Fargo lifts its NVIDIA price target to $315 ahead of the May earnings release, maintaining an Overweight rating...
A fresh web app enables 24/7 ownership of tokenized rare metals, including gold and uranium, with vault-backed receip...
Analysts at Galaxy Digital see a clear path for the CLARITY Act to be signed into law by early August if Congress mai...
Susquehanna lifts Baidu's price target to $140 while maintaining a Neutral rating, citing AI Cloud strength but ongoi...
Retail traders are adopting a pared-down framework called the three-circle test: don’t need to be a CEO to pick winni...